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Prevention of crescentic glomerulonephritis by immunoneu- of leukocytes from the blood stream into tissues requires
tralization of the fractalkine receptor CX3CR1. both the mechanisms for the leukocytes to slow down
Background. Fractalkine is a newly identified T-cell and and adhere to the vascular endothelium and the displaymonocyte/macrophage (Mφ) chemokine with a transmembrane
of recruiting signals at sufficient levels at the vicinity ofdomain and is a cell-surface protein on activated endothelium.
the intended exit site. The exit of leukocytes would beIt can mediate adhesion of cells expressing the fractalkine recep-
tor CX3CR1. These unique features make fractalkine well suited more difficult in the fast flow of the arterial system. In-
for leukocyte recruitment in tissues with high blood flow as in creasing evidence indicates that chemokines are the major
the renal glomerulus. recruiting molecules of leukocyte emigration [4–6], andMethods. Fractalkine expression in glomeruli and response
it is believed that these small soluble chemoattractantof isolated glomerular inflammatory cells to fractalkine were
molecules depend on their low-affinity binding to proteo-studied in the Wistar-Kyoto (WKY) crescentic glomerulone-
phritis model. Antibody was used to confirm the proinflamma- glycans on the endothelial surface to counter the dis-
tory role of fractalkine. persal force of blood flow and to maintain a local concen-
Results. Fractalkine was markedly induced in the endothe- tration at the vessel wall [7–10].lium of nephritic rat glomeruli, and inflammatory leukocytes
The recent identification and cloning of fractalkineinfiltrating the glomeruli expressed increased levels of CX3CR1.
[11, 12] introduced a new member with unique featuresAnti-CX3CR1 antibody treatment dramatically blocked leuko-
cyte infiltration in the glomeruli, prevented crescent formation, to the chemokine superfamily. Fractalkine has a novel
and improved renal function. CX3C motif in the chemotactic domain. It is mainly ex-Conclusions. Fractalkine plays a central role in leukocyte pressed by endothelial cells and not by hematopoietictrafficking at the endothelium in the high-flow glomerular cir-
and inflammatory cells. Most importantly, it has a trans-cuit and, in turn, implicates CX3CR1 as a prime drug target for
membrane domain and can be expressed in activatedtherapeutic intervention of endothelium-related inflammatory
diseases. endothelium as a cell-surface protein. Membrane-bound
fractalkine can directly mediate adhesion of cells express-
ing the fractalkine receptor CX3CR1, including T cells
Leukocytes are distributed throughout the body via and macrophages (Mφ) [13, 14]. Based on these features,
the vascular network. Upon receiving appropriate signals, fractalkine may be especially important for leukocyte
leukocytes are cued to exit at specific sites, frequently in recruitment in tissues with a high blood flow rate, for
the slow flow of the venular compartment, to patrol the example, the glomeruli, where the low-affinity binding
solid tissues (immune surveillance), or to mount reac- of other chemokines to proteoglycans may not withstand
tions against pathogens (inflammation) [1–3]. The exit the high shear environment [15, 16].
Infiltration of CD81 T cells and Mφ is the major mech-
anism for injury in the aggressive, crescentic glomerulo-Key words: chemokine, inflammation, glomerulus, endothelium, leuko-
cyte trafficking, blood flow. nephritis (GN) of the Wistar-Kyoto (WKY) rat induced
by administration of antiglomerular basement membrane
(GBM) antibody (Ab) [17]. Various means to inhibit in-Received for publication April 27, 1999
Accepted for publication May 17, 1999 flux of these two cell types modulate the disease to vary-
ing degrees [18–20]. Recently, the use of vMIPII, a viral 1999 by the International Society of Nephrology
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protein that blocks a number of chemokine receptors, Immunofluorescence staining
was shown to be modulatory in the WKY model [21]. Wistar-Kyoto rats were sacrificed on day 3 after the
Among the chemokine receptors influenced by vMIPII anti-GBM GN induction, and the renal tissue samples
is the fractalkine receptor CX3CR1. To investigate the were snap-frozen in Tissue-Tek (Miles Laboratories Inc.,
role of fractalkine directly in this model, an Ab to the Elkhart, IN, USA) at 2708C. For fractalkine staining, 5
CX3CR1 was prepared and compared with Ab specific mm kidney sections were reacted with horseradish perox-
for the CC chemokine receptor CCR5 in the WKY idase (HRP)-conjugated antifractalkine Ab and detected
model. Anti-CX3CR1 was found to be even more effec- with FITC-labeled anti-HRP Ab (Bethyl Laboratories,
tive than vMIPII in reducing the glomerular disease, Inc., Montgomery, TX, USA). For GBM staining, kidney
suggesting the pivotal role of fractalkine in this model. sections were reacted with FITC-labeled swine antirabbit
The striking reduction in CD81 and Mφ suggests that the IgG Ab (DAKO Corp., Carpinteria, CA, USA). Fluores-
membrane-bound nature of fractalkine is of particular cent images of the stained slides were captured in a
importance in the influx of inflammatory cells in the digital camera and merged to the phase-contrast micro-
glomerular circuit. In addition, other chemokines that scopic background.
may bind via heparin binding sites could contribute to
subsequent accumulation and activation of inflammatory Stable transfectant cells of rat CX3CR1 cDNA
cells, especially as the influx of cells likely alters glomeru- cDNA containing the open reading frame of CX3CR1lar hemodynamics and probably slows flow in segments [28] was cloned into mammalian expression vector
of the glomerular capillary. pcDNA3. HEK 293 cells were transfected with 10 mg of
plasmid DNA using LipofectAMINE reagent (Life Tech-
nologies, Inc., Gaithersburg, MD, USA). G418-resistantMETHODS
cells expressing CX3CR1 were characterized by flow cy-Production of antibodies
tometry analysis.
A polymerase chain reaction (PCR)-amplified cDNA
fragment encoding amino acids 2 to 22 of rat CCR5 Preparation of inflammatory glomerular leukocytes
protein was cloned in-frame into the E. coli expression and normal peritoneal Mφ, steady-state binding assay,
vector pETM1 [22]. The plasmid was transformed into and chemotaxis assay
E. coli host strain BL21(DE3) for the expression and
Inflammatory leukocytes were isolated from the ne-purification of His-tagged recombinant protein. The pu-
phritic glomeruli of WKY rats three days after anti-GBMrified recombinant protein was injected into a rabbit to
GN induction, following the method of Cook, Smith,raise Ab. A similar approach was used to generate rabbit
and Cattell [29]. Peritoneal Mφ were collected from nor-Ab against rat fractalkine as described previously [23].
mal rats by washing the peritoneal cavity twice with 50
ml of phosphate-buffered saline. These cells, togetherInduction, treatment, and analysis of antiglomerular
with the stable transfectants of CX3CR1, were used inbasement membrane glomerulonephritis
both steady-state binding and chemotaxis assays, whichAnti-GBM GN was induced at day 0 in WKY rats (10
were performed as previously described [30].to 12 weeks old) by intravenous injection of anti-GBM
Ab [24] at a dose of 25 ml/100 g body weight. For Ab Flow cytometry analysis
treatment, the induction of anti-GBM GN was followed
Inflammatory leukocytes isolated from the nephriticby daily intravenous injection of 0.5 ml of different Abs
glomeruli of WKY rats three days after anti-GBM GNup to eight days. Blood samples and urine excretions
induction were used in two-color flow cytometry analysis.(24-hr period) were collected on days 0, 3, 5, 7, and 9.
Cells (5 3 10 5) were suspended in Hank’s balanced saltProteinuria was assayed by the sulfosalicylic method [25].
solution (HBSS)/4% fetal calf serum (FCS) and were incu-Urine and blood creatinine were determined using a
bated with affinity-purified anti-CX3CR1 Ab or an unre-creatinine diagnostic kit (Sigma, St. Louis, MO, USA),
lated Ab at the final concentration of 6 mg/ml for 20 minutesfollowing the manufacturer’s instructions.
on ice. The cells were washed, incubated with a 1:50
RNA isolation and RNase protection assay dilution of a PE-labeled donkey antirabbit IgG F(ab9)2
(Jackson ImmunoResearch Laboratories, Inc., WestAt different time points after the induction of anti-GBM
Grove, PA, USA) for 20 minutes, and washed again.GN, the rats were sacrificed and glomeruli were prepared
These cells were next stained with FITC-labeled, cell-as previously described [25]. Total RNA was isolated from
specific Abs. For the identification of T cells, the cellsglomeruli using a one-step method [26]. Five micrograms
were reacted with FITC-labeled mouse antirat CD3of total RNA from each sample were used for chemokine
monoclonal antibody (mAb; Pharmingen, San Diego,mRNA expression analysis by RNase protection assay,
following a previously described protocol [27]. CA, USA). For identification of macrophages, the cells
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were fixed in freshly prepared HBSS/2% paraformalde-
hyde for one hour on ice, washed, and permeabilized
with 0.1% Saponin (Sigma) in staining buffer for one
hour on ice. The permeabilized cells were reacted with
FITC-labeled anti-ED1 mAb (Biosource International,
Camarillo, CA, USA) or FITC-labeled anti-CD45RA
MAb OX-33 (Pharmingen) as a control. Stained cells
were analyzed on a FACScan station (Becton Dickinson
Immunocytometry Systems, San Jose, CA, USA). Cells
were gated according to their forward and side scatter,
and 10,000 gated events were collected for analysis.
Histopathology
Kidney tissue samples were fixed in 10% neutralized
buffered formalin (NBF) or methanol-Carnoy fixative
solution and were embedded in paraffin. For light mi-
croscopy examination, 5 mm paraffin sections of NBF-
fixed tissues were stained with periodic acid-Schiff (PAS)
reagent. For identification of infiltrating leukocytes, 5 mm
paraffin sections of the methanol-Carnoy–fixed tissues
were immunohistochemically stained for CD81 and
ED11 cells, as previously described [30].
RESULTS
Increased fractalkine expression in the endothelium of
nephritic glomeruli
Induction of anti-GBM GN in WKY rats led to a pro-
found increase in the expression of fractalkine mRNA
(Fig. 1A). The induction of fractalkine mRNA was prom-
inent on days 3 and 5 after the Ab injection, persisted
Fig. 1. Characterization of chemokine and chemokine receptor expres-through day 7, and started to subside by day 9. When
sion in the glomeruli of Wistar-Kyoto (WKY) rats. (A) mRNA expres-the glomeruli were fractionated by an enzyme digestion
sion of fractalkine. Antiglomerular basement membrane (GBM) glo-
method [29], it was found that fractalkine was expressed merulonephritis (GN) was induced in WKY rats on day 0. On days 0,
3, 5, 7, and 9, the rats were sacrificed, and glomerular RNA samplesexclusively in glomerular resident cells. Immunofluores-
were prepared for analysis. Probes contain polylinker regions and arecence staining of fractalkine in the nephritic kidney
longer than the protected bands. Rat ribosomal L32 gene was used asshowed a nonlinear pattern typical of glomerular endothe- a housekeeping gene. Each lane represents one rat sample. (B, facing
lium, in contrast to the linear staining of anti-GBM Ab page, top panels) Immunofluorescence staining of fractalkine (left) and
GBM (right) in the kidneys of WKY rats with anti-GBM GN. Thethat outlined the GBM (Fig. 1B). Fractalkine staining was
green fluorescent staining concentrated in the glomeruli is evident overonly detected in nephritic glomeruli, but not in normal the purple phase contrast microscopic background. The arrow in the
control kidneys (data not shown). Fractalkine-absorbed left panel denotes a small vessel positively stained for fractalkine. (C)
mRNA expression of chemokine receptors CX3CR1, CCR2, and CCR5.Ab and preimmune serum did not stain nephritic glomer-
Each lane represents one rat sample. (D, p. 616) Flow cytometry analysisuli, indicating that the fractalkine staining was specific. of CX3CR1 expression in ED11 Mφ and CD31 T cells isolated from
nephritic glomeruli. Two-dimensional dot plots showing glomerular
Increased CX3CR1 expression in glomerular leukocytes stained with (A) an unrelated Ab and anti-CD3 Ab; (B)
anti-CX3CR1 Ab and anti-CD3 Ab; (C) an unrelated Ab and anti-inflammatory leukocytes and response
CD45RA Ab (as isotype control); and (D) anti-CX3CR1 Ab and anti-of these cells to fractalkine
ED1 Ab.
Concordant with the increased expression of fractal-
kine, the expression of CX3CR1 mRNA was also in-
creased in nephritic glomeruli (Fig. 1C). The time-course
matory leukocytes isolated from nephritic glomeruliof CX3CR1 mRNA expression mirrored that of its ligand.
(Fig. 1D). Two-color flow cytometry analysis further lo-As a comparison, the mRNA expression of several CC
calized CX3CR1 expression to CD31 T cells and ED11chemokine receptors was also examined. CCR2 and
Mφ. CX3CR1 expressed in these cells was characterizedCCR5 were induced between days 3 and 7 (Fig. 1C),
in functional studies. In steady-state binding assays, ne-but not CCR1 and CCR4 (not shown). Flow cytometry
analysis showed that CX3CR1 was expressed in inflam- phritic leukocytes showed a specific binding of 125I-labeled
Fig. 3. Photomicrographs (3400 magnification) of the glomeruli of antiglomerular basement membrane (GBM) glomerulonephritis (GN) in WKY
rats treated with normal rabbit serum (NRS) or rabbit antibodies (Abs) against CX3CR1 (anti-CX3CR1) or CCR5 (anti-CCR5). Kidney sections
were immunohistochemically stained for CD81 cells or ED11 Mφ or were stained with periodic acid-Schiff (PAS) reagent. Sections shown were
sampled on day 3 (for CD8 staining) or day 5 (for ED1 and PAS staining) after anti-GBM Ab injection.
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Fig. 1. See legend on p. 614.
fractalkine similar to that of HEK 293 cells transfected we investigated whether normal peritoneal Mφ would
respond to fractalkine. Normal peritoneal Mφ showedwith CX3CR1 cDNA (Fig. 2A). The binding was inhib-
little fractalkine binding (data not shown), and althoughited by anti-CX3CR1 Ab (Fig. 2B), but not by anti-CCR5
responding well to RANTES (not shown), it did notAb (data not shown). In chemotaxis assays, the glomeru-
respond to fractalkine in the chemotaxis assay (Fig. 2C).lar infiltrates displayed a robust chemotactic response
These results suggest that CX3CR1 receptor regulationto fractalkine (Fig. 2C). The chemotaxis response was
may be an important step in fractalkine recruitment andinhibited by anti-CX3CR1 Ab, but not by anti-CCR5 Ab
activation of leukocytes.(Fig. 2D). As a control, glomerular leukocyte chemotaxis
response to RANTES was inhibited by anti-CCR5 Ab, Prevention of crescent glomerulonephritis by anti-
CX3CR1 antibody treatmentbut not by anti-CX3CR1 Ab (Fig. 2D). Because a basal
level of CX3CR1 is expressed in normal mononuclear Because the anti-CX3CR1 Ab was capable of blocking
glomerular leukocyte chemotaxis in vitro, the effect ofcells [13] and normal resident Mφ (our unpublished data),
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Fig. 2. Leukocyte binding of and chemotaxis to fractalkine. (A) Com-
petitive binding assay of 125I fractalkine with activated leukocytes from
nephritic glomeruli (left panel) and HEK 293 cells transfected with
CX3CR1 (right panel). (B) Anti-CX3CR1 antibody (Ab) inhibition of
125I fractalkine binding by inflammatory glomerular leukocytes and
CX3CR1 transfectants. (C) Fractalkine-induced chemotaxis of inflam-
matory glomerular leukocytes (j) and normal peritoneal Mφ (h). (D)
Effects of anti-CX3CR1 and anti-CCR5 Abs on chemotaxis responses
of inflammatory glomerular leukocytes to fractalkine (upper panel) and
RANTES (lower panel).
this Ab on the progress of anti-GBM GN was tested in treatment attenuated glomerular leukocyte infiltration in
the experimental group, with significant reduction invivo. The induction of GN in WKY rats was followed
by treatment with daily injections of anti-CX3CR1 Ab both the ED11 Mφ and CD81 cells (Fig. 3). The blocking
effect was specific; CX3CR1-adsorbed anti-CX3CR1 Abor normal rabbit serum as a control. In the control group,
a prominent accumulation of CD81 cells and ED11 Mφ failed to show any reduction in leukocyte infiltration
(data not shown). As a comparison, anti-GBM GN inin the glomeruli was observed (Fig. 3). Anti-CX3CR1 Ab
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Fig. 4. Effect of various antibody (Ab) treat-
ments [normal rabbit serum (NRS; j); anti-
CX3CR1 Ab (h); anti-CCR5 Ab ( ) on the
antiglomerular basement membrane (GBM)
glomerulonephritis (GN) in Wistar-Kyoto
(WKY) rats. (A) Quantitation of CD81 and
ED11 infiltrates per glomerulus. Kidney sec-
tions stained as shown in Figure 3 were exam-
ined and counted for positively stained cells.
Data represent 100 glomeruli counted from
three rat (N 5 3) kidney sections and are
expressed as mean 6 sem. The asterisk de-
notes significant difference compared with
NRS-treated group (P , 0.01, Student’s t-
test). (B) Twenty-four–hour urinary protein
excretion. Results were sampled from six rats
per group (N 5 6) and were expressed as
mean 6 sem. The asterisk denotes a significant
difference compared with NRS-treated group
(P , 0.01, Student’s t-test).
WKY rats was also treated with anti-CCR5 Ab. Anti- with the proteinuria level in different groups of rats (data
not shown).CCR5 Ab treatment led to a moderate reduction in leu-
kocyte infiltration (Fig. 3). The quantitation of glomeru-
lar leukocyte infiltration in different groups of rats is DISCUSSION
shown in Figure 4A. The effects of various Ab treatments
The results establish a central role for fractalkine andon leukocyte infiltration were also reflected in the overall
its receptor, CX3CR1, in the pathogenesis of crescentickidney histology (Fig. 3). The control group of rats dis-
GN in the WKY rat. In vitro studies have indicated thatplayed severe glomerular hypercellularity and crescent
fractalkine can be induced as a membrane protein information in the kidneys. In stark contrast, the anti-
activated endothelial cells and can mediate both chemo-CX3CR1 Ab-treated group had minimal pathological taxis and adhesion of cells bearing CX3CR1 [11, 13].damage in the kidneys; crescentic formation, a major
Based on these in vitro studies, it has been suggested that
characteristic of this model, was virtually abolished by fractalkine may be specialized for directing leukocyte
the anti-CX3CR1 Ab treatment. As expected from their trafficking at the endothelium and that, in turn, fractal-
effects on glomerular leukocyte infiltration, the anti- kine/CX3CR1 interactions could be of critical importance
CCR5 Ab treatment showed a moderate beneficial effect at the interface between the leukocyte cell surface and
over the control group. Finally, urine protein excretions the endothelium, especially in high-flow situations such
and serum creatinine levels were monitored in the con- as the renal glomeruli [15, 16].
trol and treatment groups of rats as indications of renal The observation that activated glomerular leukocytes
function. Normal renal function was largely maintained show a greater response to fractalkine than normal peri-
in anti-GBM GN WKY rats treated with anti-CX3CR1 toneal Mφ suggests that the regulation of CX3CR1 ex-
Ab. Urinary protein of the anti-CX3CR1 Ab-treated pression contributes in an important way in the control
group was remarkably low, being less than 15% of that of the fractalkine/CX3CR1 interaction. It was reported
in the control group at all time points (P , 0.01; Fig. that the fractalkine/CX3CR1 interaction has a hybrid
4B). Anti-CCR5 Ab treatment also reduced proteinuria, function of adhesion and chemotaxis and suggested that
although not as effectively as the anti-CX3CR1 Ab treat- the fractalkine/CX3CR1-mediated adhesion was inde-
pendent of the fractalkine/CX3CR1 signaling for chemo-ment (Fig. 4B). The serum creatinine level correlated
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